iPhone Charging Gets a Makeover & Why Cold Medicines are Useless
Sep 13, 2023
25:26
auto_awesome Snipd AI
Apple's big product event reveals exciting tidbits about the iPhone 15. A covid-era government program affects poverty rates. FDA declares a key ingredient in cold medicines ineffective. The UFC & WWE merger debuts at the NYSE. Surge pricing is coming for your booze.
Read more
AI Summary
AI Chapters
Episode notes
auto_awesome
Podcast summary created with Snipd AI
Quick takeaways
The new iPhone 15 will come with a USB-C charging port, aligning with the EU mandate for consumer electronics, and also features incremental upgrades and maintains the same pricing as the previous year.
The US poverty rate has risen to 12.4% in 2022, with child poverty doubling due to the expiration of the expanded child tax credit, emphasizing the impact of policy choices and the need for continued support to alleviate poverty.
Deep dives
Apple unveils iPhone 15 with USB-C charging port
Apple announced the new iPhone 15 at their recent event, revealing that it will come with a USB-C charging port. This move comes ahead of an EU mandate requiring most consumer electronics to be USB-C compatible by 2024. The new iPhone also features a snazzy new camera with pet recognition and a titanium finish option. Overall, the iPhone 15 offers incremental upgrades to an already great phone and maintains the same pricing model as the previous year.
US poverty rate rises due to expiration of child tax credit
The US poverty rate has increased significantly, with a rise to 12.4% in 2022 compared to 7.8% the previous year. The child poverty rate more than doubled, going from a record low of 5.2% in 2021 to 12.4% in 2022. This increase can be attributed to the expiration of the expanded child tax credit, which had been successful in cutting child poverty in half. The report highlights the impact of policy choices and the need for continued support and measures to alleviate poverty.
Phenylephrine decongestant effectiveness called into question
An FDA advisory panel has raised doubts about the effectiveness of phenylephrine, a popular decongestant found in over 260 oral and sinus medicines. Recent studies have shown that phenylephrine does not provide any better relief for stuffy noses than a placebo, even at high dosages. This news is concerning for the over-the-counter cough, sinus, and flu market, which generated around $5 billion in sales in 2021 from products containing phenylephrine. If the FDA adopts the panel's recommendation, it could lead to the reformulation of these products and the removal of phenylephrine as an active ingredient.
Episode 146: Neal and Toby list off all the exciting tidbits from Apple's big product event, including the iPhone 15 reveal. Next, how a covid-era government program is affecting poverty rates in America. Plus, quick relief from a cold may be gone as FDA declares a key ingredient in cold medicines ineffective. Then, the UFC & WWE merger debuts at the NYSE and promotions are doing the opposite of what employers want. Lastly, surge pricing is coming for your booze.